Fibrinogen (Factor I)
Fibrinogen is the soluble plasma glycoprotein that becomes insoluble fibrin at the final step of both coagulation pathways, forming the structural scaffold of haemostatic clots. Its trinodular hexameric architecture — two outer D-domains flanking a central E-domain — is the physical basis for fibrin polymerisation: thrombin exposes "knob A" (Asn–Gly, Aα chain) and "knob B" (Gly–His, Bβ chain) that fit into complementary "holes a and b" in adjacent fibrin molecules. Factor XIIIa (thrombin-activated transglutaminase) then introduces γ-γ and α-α isopeptide crosslinks that transform the initially weak polymeric gel into a mechanically robust clot resistant to fibrinolysis. Fibrinogen is also a positive acute-phase reactant (IL-6/STAT3-driven hepatic upregulation 3–5-fold in inflammation), explaining its role as an independent cardiovascular risk factor — elevated levels increase blood viscosity, platelet reactivity, and direct thrombotic potential.
Structure — Trinodular Hexamer
Fibrinogen has a characteristic trinodular architecture visible by electron microscopy: two distal D-domains (outer nodules) connected by coiled-coil regions to a central E-domain (inner nodule) containing the N-termini of all 6 chains joined by a disulfide ring (the N-terminal disulfide knot, NDK). The fibrinopeptides A (FpA, 16 aa from Aα) and B (FpB, 14 aa from Bβ) are located in the E-domain and are removed by thrombin to initiate polymerisation.
| Chain | Gene | MW | Key structural/functional features |
|---|---|---|---|
| Aα | FGA | ~95 kDa | Fibrinopeptide A (residues 1–16) at N-terminus; RGD sequence for platelet αIIbβ3 (GPIIb/IIIa) binding; long C-terminal αC domain dimerises across molecules |
| Bβ | FGB | ~55 kDa | Fibrinopeptide B (residues 1–14) at N-terminus; cleaved second by thrombin (slower); βC domain contains "hole b" |
| γ | FGG | ~47 kDa | C-terminal AGDV dodecapeptide binds platelet αIIbβ3; Lys406/Gln398-407 are FXIIIa crosslink sites (γ-γ dimer bonds); contains "hole a" |
Mechanism — Fibrin Clot Formation and Resolution
COAGULATION CASCADE (intrinsic or extrinsic pathway)
│
▼ THROMBIN (Factor IIa) activated
│
STEP 1: Thrombin cleaves FpA from Aα chain (Arg16–Gly17 bond)
→ "Knob A" (Gly-Pro-Arg) exposed
→ Knob A fits into "Hole a" in γC domain of adjacent fibrin molecule
→ Rapid end-to-middle polymerisation → fibrin protofibrils
│ (D:E interactions; half-staggered double-stranded)
│
STEP 2: Thrombin cleaves FpB from Bβ chain (Arg14–Gly15) [slower]
→ "Knob B" (Gly-His-Arg) exposed
→ Knob B fits into "Hole b" in βC domain
→ Lateral association of protofibrils → thicker fibres + branching
→ FIBRIN GEL formed (mechanically weak, soluble in urea)
│
STEP 3: FACTOR XIIIa crosslinking (ESSENTIAL for clot stability)
Thrombin + Ca²⁺ activates Factor XIII → FXIIIa (transglutaminase)
FXIIIa catalyses:
γ-γ CROSSLINKS: Lys406(γ) + Gln398/399(γ') → isopeptide bond
→ γ-γ dimer (fast, minutes; ↑mechanical strength)
α-α CROSSLINKS: Multiple Lys-Gln bonds across Aα chains
→ high-MW α-polymer (slower, hours)
Also: FXIIIa crosslinks α₂-antiplasmin into clot → fibrinolysis resistance
FIBRINOLYSIS (clot resolution):
tPA (endothelium) or uPA → plasminogen → PLASMIN
Plasmin cleaves fibrin at Lys/Arg → FDPs (fibrin degradation products)
Key product: D-DIMER (γ-γ crosslinked D-D fragment)
→ Specific for crosslinked fibrin (not fibrinogen) degradation
→ Diagnostic marker for DVT/PE/DIC
Inhibitors: α₂-antiplasmin (rapid plasmin scavenger); PAI-1 (↑in obesity)
Acute-phase upregulation
During systemic inflammation, IL-6 (the dominant inducer) → hepatocyte gp130/JAK1 → STAT3 → binds STAT3-response elements in FGA, FGB, and FGG promoters → 3–5-fold increase in fibrinogen mRNA and protein within 12–24 hours. This drives elevated ESR (erythrocyte sedimentation rate — fibrinogen promotes rouleaux formation), increased blood viscosity, and increased thrombotic risk. CRP often rises simultaneously (another IL-6/STAT3-driven positive acute-phase protein) — making fibrinogen a complementary (not redundant) inflammatory biomarker.
Physiological Roles
Platelet scaffolding: Soluble fibrinogen bridges two activated platelets via αIIbβ3 (GPIIb/IIIa) integrin — RGD sequence on Aα chain and AGDV dodecapeptide on the γ-chain C-terminus. This is the molecular basis of platelet aggregation (the primary haemostatic plug), and the reason GPIIb/IIIa antagonists (abciximab, eptifibatide, tirofiban) are potent antithrombotic agents — they block fibrinogen bridging, not platelet activation per se.
Cardiovascular risk marker: Elevated fibrinogen (>3.5 g/L) is associated with increased risk of MI (independent of LDL-C, smoking — Northwick Park Heart Study), ischaemic stroke, and peripheral arterial disease. Mechanisms: pro-coagulant (fibrin clot formation), rheological (↑erythrocyte aggregation → ↑blood viscosity → ↑endothelial shear stress), and pro-inflammatory (fibrinogen fragments activate leukocytes via Mac-1/CR3 integrin).
Pathology
| Condition | Mechanism | Clinical features |
|---|---|---|
| Afibrinogenaemia | Autosomal recessive null mutations in FGA, FGB, or FGG → no fibrinogen synthesised | Severe bleeding from birth (umbilical cord, circumcision, haemarthroses); paradoxically also thrombosis (fibrinogen normally inhibits thrombin); treat with fibrinogen concentrate or FFP |
| Hypofibrinogenaemia | Heterozygous loss-of-function → fibrinogen <1.5 g/L | Mild-moderate bleeding tendency; often asymptomatic; fibrinogen <1 g/L → significant haemorrhagic risk; diagnose: Clauss fibrinogen assay (functional) |
| Dysfibrinogenaemia | >700 structural variants described; structural changes impair polymerisation (→ bleeding) or fibrinolysis resistance (→ thrombosis) | Fibrinogen antigen normal but functional Clauss assay reduced; prolonged PT/APTT in some; diagnose by SPEP/immunofixation + functional assay discordance |
| Disseminated intravascular coagulation (DIC) | Systemic thrombin generation (sepsis, obstetric catastrophe, malignancy, major trauma) → fibrinogen consumption → ↓fibrinogen + ↑D-dimer + ↓platelets + ↑PT/APTT | Diffuse microvascular thrombosis + paradoxical haemorrhage; diagnose: ↓fibrinogen + ↑D-dimer + schistocytes; treat underlying cause; FFP + cryoprecipitate (>10 g fibrinogen/pool) if fibrinogen <1.5 g/L and bleeding |
| DVT/PE | Fibrin-rich "red thrombus" (Virchow triad: stasis + hypercoagulability + endothelial injury); D-dimer released by fibrinolysis of thrombus → ↑serum D-dimer | D-dimer has high sensitivity (92–96%) but low specificity for VTE; D-dimer <500 ng/mL + low pre-test probability = rule out (Wells criteria); confirmed by compression USS or CTPA; treat with anticoagulation (DOACs, LMWH) |
| Elevated fibrinogen / CVD risk | Chronic inflammation + genetic variants (FGB -455G>A promoter polymorphism → ↑fibrinogen) → ↑plasma fibrinogen → ↑viscosity, ↑thrombotic potential, ↑leukocyte Mac-1 activation | Independent MI and stroke risk predictor; modest reduction with statins (~10%), fibrate/niacin (<15%); primary treatment is management of the underlying inflammatory condition |
Pharmacology / Clinical Use
Fibrinogen concentrate (RiaSTAP, Haemocomplettan): Lyophilised human fibrinogen; target level >1.5–2 g/L in active haemorrhage or before invasive procedures; preferred over cryoprecipitate in many European centres (pathogen-inactivated, standardised dose, no thawing needed). FLOSEAL and TISSEEL use fibrinogen + thrombin in topical haemostatic matrix for surgical haemostasis.
Fibrinolysis monitoring — D-dimer: D-dimer is the gold-standard marker for active fibrinolysis. Critical clinical roles: (1) DVT/PE rule-out (<500 ng/mL, age-adjusted cut-off <10 × age in patients >50 years); (2) DIC diagnosis (↑D-dimer + ↓fibrinogen + ↓platelets + schistocytes); (3) COVID-19 coagulopathy (markedly ↑D-dimer >1,000 ng/mL predicts severe disease and need for anticoagulation); (4) aortic dissection (D-dimer <500 ng/mL has ~95% NPV for Type A).
D-dimer interpretation: D-dimer is highly sensitive but not specific — elevated in PE, DVT, DIC, pregnancy, surgery, trauma, inflammation, malignancy, atrial fibrillation, and with age. D-dimer should only be ordered in patients with low-to-intermediate pre-test probability (Wells criteria ≤4 for DVT, ≤6 for PE) — if pre-test probability is high, proceed directly to imaging. Age-adjusted cut-off (age × 10 ng/mL in patients >50 years) reduces false-positives and unnecessary imaging by ~25%.
Connections
References
- Berg JM, Tymoczko JL, Stryer L. Biochemistry. 9th ed. W.H. Freeman; 2019.
- Murphy K, Weaver C. Janeway's Immunobiology. 9th ed. Garland Science; 2017.
- Weisel JW, Litvinov RI. Fibrin formation, structure and properties. Subcell Biochem. 2017;82:405-456. doi:10.1007/978-3-319-49674-0_13
- Lowe GD, et al. (Northwick Park Heart Study II). Plasma fibrinogen and coronary heart disease. Lancet. 1988;1(8592):986-8. doi:10.1016/s0140-6736(88)90153-4
- Toh CH, Hoots WK. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the ISTH. J Thromb Haemost. 2007;5(3):604-6. doi:10.1111/j.1538-7836.2007.02441.x